MiNK Therapeutics, Inc. (INKT) DCF Valuation

Mink Therapeutics, Inc. (Inkt) Valoración de DCF

US | Healthcare | Biotechnology | NASDAQ
MiNK Therapeutics, Inc. (INKT) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

MiNK Therapeutics, Inc. (INKT) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Hazte cargo de tu análisis de valoración de Mink Therapeutics, Inc. (Inkt) con nuestra calculadora DCF de vanguardia! Esta plantilla de Excel viene precargada con datos reales (Inkt), lo que le permite ajustar preventos y supuestos para un cálculo preciso del valor intrínseco de Mink Therapeutics, Inc.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .7 .0 .0 2,704.7 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 -100 0 0 -100 -50 -50 -50 -50 -50
EBITDA -22.2 -13.7 -27.7 -30.8 -22.3 .0 .0 .0 .0 .0
EBITDA, % -3219.79 100 100 -1.14 100 39.77 39.77 39.77 39.77 39.77
Depreciation .0 .1 .1 .1 .2 .0 .0 .0 .0 .0
Depreciation, % 5.34 100 100 0.00450131 100 61.07 61.07 61.07 61.07 61.07
EBIT -22.2 -13.8 -27.8 -30.9 -22.5 .0 .0 .0 .0 .0
EBIT, % -3225.13 100 100 -1.14 100 39.77 39.77 39.77 39.77 39.77
Total Cash .3 2.7 38.9 19.6 3.4 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 0 100 100 0 100
Inventories .1 1.0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 12.72 100 100 0 100 62.54 62.54 62.54 62.54 62.54
Accounts Payable 2.5 3.1 3.0 5.8 3.9 .0 .0 .0 .0 .0
Accounts Payable, % 356.16 100 100 0.21529 100 80.04 80.04 80.04 80.04 80.04
Capital Expenditure -.4 -.1 -.2 -.3 -.1 .0 .0 .0 .0 .0
Capital Expenditure, % -61.84 100 100 -0.00924472 100 -12.37 -12.37 -12.37 -12.37 -12.37
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -24.2 -13.3 -21.3 -27.4 -22.5 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -22.2 -13.6 -20.6 -24.7 -24.2 -3.9 .0 .0 .0 .0
WACC, % 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39
PV UFCF
SUM PV UFCF -3.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -4
Net Debt -3
Equity Value 0
Diluted Shares Outstanding, MM 34
Equity Value Per Share -0.01

What You Will Get

  • Comprehensive INKT Financials: Access to both historical and projected data for precise valuation.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Real-Time Calculations: Intrinsic value and NPV are updated automatically.
  • Scenario Analysis: Explore various scenarios to assess MiNK Therapeutics' future performance.
  • User-Friendly Design: Crafted for professionals while remaining easy to navigate for newcomers.

Key Features

  • Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for MiNK Therapeutics, Inc. (INKT).
  • WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with customizable parameters specific to the biotech sector.
  • Adjustable Forecast Assumptions: Easily modify growth projections, capital expenditures, and discount rates relevant to MiNK Therapeutics, Inc. (INKT).
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for MiNK Therapeutics, Inc. (INKT).
  • Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.

How It Works

  • Step 1: Download the prebuilt Excel template containing MiNK Therapeutics' data.
  • Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly see the recalculated results, including MiNK Therapeutics' intrinsic value.
  • Step 5: Make well-informed investment decisions or create reports based on the outputs.

Why Choose This Calculator for MiNK Therapeutics, Inc. (INKT)?

  • User-Friendly Interface: Tailored for both novice and seasoned users.
  • Customizable Inputs: Adjust parameters easily to suit your financial analysis.
  • Real-Time Updates: Monitor immediate changes to MiNK Therapeutics' valuation as you modify inputs.
  • Preloaded Data: Comes with MiNK Therapeutics' latest financial information for swift evaluations.
  • Endorsed by Experts: Utilized by investors and analysts for strategic decision-making.

Who Should Use This Product?

  • Investors: Accurately assess MiNK Therapeutics' fair value before making investment decisions.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to MiNK Therapeutics, Inc. (INKT).
  • Consultants: Efficiently customize the template for valuation reports tailored to clients focused on MiNK Therapeutics.
  • Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
  • Educators: Implement it as a teaching resource to illustrate valuation methodologies in the biotech sector.

What the Template Contains

  • Pre-Filled Data: Includes MiNK Therapeutics’ historical financials and projections.
  • Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
  • Key Financial Ratios: Analyze MiNK Therapeutics’ profitability, efficiency, and leverage.
  • Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
  • Clear Dashboard: Charts and tables summarizing key valuation results.

No products were found matching.